PISCATAWAY, NJ – Camber Pharmaceuticals has expanded its injectable offerings with the launch of Chlorpromazine HCl Injection, USP, a versatile medication used in the treatment of a wide range of psychiatric and medical conditions.
Chlorpromazine HCl Injection is indicated for the treatment of schizophrenia, severe behavioral problems in children, and manic-depressive illness. It is also used to control nausea and vomiting, relieve preoperative apprehension, treat acute intermittent porphyria, manage symptoms of tetanus, address intractable hiccups, and as a short-term treatment for hyperactivity and conduct disorders in children.
The product is now available in two strengths and package sizes:
- 25 mg/mL – 25 x 1 mL single-dose vials
- 50 mg/2 mL (25 mg/mL) – 25 x 2 mL single-dose vials
The launch of Chlorpromazine HCl Injection, USP reflects Camber’s ongoing commitment to providing high-quality, cost-effective medications to healthcare providers and patients across the United States.
For more information, visit www.camberpharma.com.
